Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov-Dec;22(6):728-734.
doi: 10.4103/ijem.IJEM_424_18.

Once Weekly Dulaglutide Therapy in Type 2 Diabetic Subjects, Real-world Evidence from a Tertiary Care Diabetes Center in India

Jasjeet S Wasir  1 , Ambrish Mithal  1 , Paras Agarwal  1 , Apeksha Mittal  1
Affiliations

Once Weekly Dulaglutide Therapy in Type 2 Diabetic Subjects, Real-world Evidence from a Tertiary Care Diabetes Center in India

Jasjeet S Wasir et al. Indian J Endocrinol Metab. 2018 Nov-Dec.

Abstract

Aims: To evaluate the real-world efficacy, durability, and side-effect profile of once weekly GLP1RA: dulaglutide in Indian type 2 diabetes mellitus (T2DM) patients.

Materials and methods: A retrospective observational study. Data for efficacy (HbA1c and weight), adherence/discontinuation and patient reported side-effects, of 117 patients who were prescribed dulaglutide were analyzed.

Results: Final analysis was done on complete data of 74 patients (6 months follow-up), this indicated that dulaglutide is effective (mean-reduction at 6 months of: HbA1c; 0.87% and weight; 3.8 kg). Subjects with a poorer glycemic control (greater HbA1c) or greater weight at initiation had a better fall in HbA1c and weight reduction at the end of the study. The most common side-effects were gastrointestinal (15% nausea and 6% loose motions). Also, 25% (n = 19) of our study subjects discontinued dulaglutide because of gastrointestinal side-effects.

Conclusion: Our real-world experience is well aligned to systematic data of the randomized controlled trials (RCTs) regarding the efficacy of dulaglutide in the treatment of T2DM (our study vs. RCTs; HbA1c reduction: 0.87% vs. 0.78% to 1.64%, weight reduction: 3.8 vs. 0.3 to 3 kg). The most common side-effects and reason for discontinuation were gastrointestinal side-effects. Finally, by virtue of their observed benefit, we expect a superior cardiovascular risk-reduction with dulaglutide use in our population.

Keywords: Dulaglutide; real-world experience; type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Flow of this study
Figure 2
Figure 2
(a) Dulaglutide naïve group (n = 74), relationship between baseline HbA1c and HbA1c difference at 6 months (Pearson's correlation coefficient of 0.600 (P < 0.001). (b) Dulaglutide naïve group (n = 74), relationship between baseline weight and weight difference at 6 months (Pearson's correlation coefficient 0.320, P value = 0.005). (c) Patients on dulaglutide and not on any SGLT-2 inhibitor (n = 47), relationship between baseline HbA1c and HbA1c difference at 6 months (Pearson's correlation 0.719; P value <0.001). (d) Patients on dulaglutide and not on any SGLT-2 inhibitor (n = 47), relationship between baseline weight and weight difference at 6 months (Pearson's correlation 0.263; P value 0.074)
See this image and copyright information in PMC

References

    1. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: Dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8:29. - PMC - PubMed
    1. van Dieren S, Beulens JW, van der Schouw YT, Grobbee DE, Neal B. The global burden of diabetes and its complications: An emerging pandemic. Eur J Cardiovasc Prev Rehabil. 2010;17(Suppl 1):S3–8. - PubMed
    1. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93. - PubMed
    1. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: A review of their efficacy and tolerability. Diabetes Care. 2011;34(Suppl 2):S279–84. - PMC - PubMed
    1. Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1) Diabetes Care. 2014;37:2159–67. - PubMed